0001209191-17-029021.txt : 20170501
0001209191-17-029021.hdr.sgml : 20170501
20170501185223
ACCESSION NUMBER: 0001209191-17-029021
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20170427
FILED AS OF DATE: 20170501
DATE AS OF CHANGE: 20170501
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Kite Pharma, Inc.
CENTRAL INDEX KEY: 0001510580
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 000000000
STATE OF INCORPORATION: DE
BUSINESS ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
BUSINESS PHONE: (310) 824-9999
MAIL ADDRESS:
STREET 1: 2225 COLORADO AVENUE
CITY: SANTA MONICA
STATE: CA
ZIP: 90404
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: CHAMPSI FARAH
CENTRAL INDEX KEY: 0001198321
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36508
FILM NUMBER: 17802470
MAIL ADDRESS:
STREET 1: ONE EMBARCADERO CENTER SUITE 3700
CITY: SAN FRANCISCO
STATE: CA
ZIP: 94111
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2017-04-27
0
0001510580
Kite Pharma, Inc.
KITE
0001198321
CHAMPSI FARAH
C/O KITE PHARMA, INC.
2225 COLORADO AVENUE
SANTA MONICA
CA
90404
1
0
0
0
Common Stock
2017-04-27
4
S
0
16551
82.77
D
7579
I
See Footnote
Common Stock
2017-04-28
4
S
0
2617
82.59
D
4962
I
See Footnote
Common Stock
79152
D
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $83.24, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
The securities are held of record by APVIII. Alta Partners Management VIII, LLC ("APMVIII") is the general partner of APVIII. The reporting person is a managing director of APMVIII and exercises shared voting and investment power with respect to the shares owned by APVIII. The reporting person disclaims beneficial ownership of such securities, except to the extent of her proportionate pecuniary interest therein.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $82.50 to $82.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth above.
/s/ David M. Tanen, Attorney-in-Fact
2017-05-01